Proceeds used for research and development activities for EVK-001
By Devika Patel
Knoxville, Tenn., Sept. 24 - Evoke Pharma, Inc. said it priced its $25.2 million initial public offering of stock with a $3.78 million greenshoe. The deal was announced May 24.
The company will sell 2.1 million common shares at $12.00 per share.
Aegis Capital Corp. is the sole bookrunning manager.
Settlement is expected Sept. 30.
Proceeds will be used for research and development activities for EVK-001, working capital and other general corporate purposes.
The specialty pharmaceutical company is based in San Diego. The company expects its shares will trade on the Nasdaq under the symbol "EVOK."
| Issuer: | Evoke Pharma, Inc.
|
| Issue: | Common stock
|
| Amount: | $25.2 million
|
| Greenshoe: | $3.78 million
|
| Shares: | 2.1 million
|
| Price: | $12.00
|
| Warrants: | No
|
| Bookrunner: | Aegis Capital Corp.
|
| Co-managers: | Cantor Fitzgerald & Co. and Feltl and Co., Inc.
|
| Announcement date: | May 24
|
| Pricing date: | Sept. 24
|
| Settlement date: | Sept. 30
|
| Stock exchange: | Nasdaq: EVOK
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
